ASCO 2023 | Current developments in FGFR inhibitors for urothelial cancer

Daniel Petrylak, MD, Yale School of Medicine, New Haven, CT, gives an overview of FGFR inhibition in urothelial cancer. With the exception of erdafitinib, relatively few FGFR inhibitors including infigratinib and rogaratinib have shown success in clinical trials. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.